YM 7555
Alternative Names: AD DNA Vaccine - VITRUVIAN BioMedical; Alzheimer's disease vaccine - VITRUVIAN BioMedical; YM7555Latest Information Update: 28 Nov 2021
At a glance
- Originator Immunotherapy Development; Tokyo Metropolitan Institute of Medical Science
- Developer VITRUVIAN BioMedical
- Class Alzheimer vaccines; DNA vaccines; Gene therapies
- Mechanism of Action Amyloid beta-protein inhibitors; Immunostimulants; Tau protein inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Alzheimer's disease
Most Recent Events
- 28 Nov 2021 No recent reports of development identified for preclinical development in Alzheimer's-disease in USA (Parenteral)
- 28 Nov 2021 No recent reports of development identified for preclinical development in Alzheimer's-disease(Prevention) in USA (Parenteral)
- 05 Oct 2018 VITRUVIAN BioMedical plans phase Ib/IIa trial for Alzheimer's disease in 2019 (VITRUVIAN BioMedical website, October 2018)